School of Medicine
  • Print

School staff listing

People listings by divisions


Image of Delyan Ivanov

Delyan Ivanov

Postdoctoral Research Associate,



Delyan has obtained his MPharm degree from the Medical University of Sofia, Bulgaria. After a year in industry, working on solid dosage forms, he joined the University of Nottingham in 2010 as a postgraduate research student in the Centre for Doctoral Training (CDT) in Targeted therapeutics sponsored by the EPSRC and AstraZeneca. Delyan's PhD work at the School of Pharmacy aimed to develop novel nanoparticle-based local treatments for children's brain tumours. During his PhD, Delyan also established a series of three-dimensional cell culture models of brain tumours using human neural stem cells and human medulloblastoma cell lines cultured as spheroid single and co-cultures in a high-throughput format. The EPSRC has awarded Delyan with the prestigious Doctoral Prize allowing him to work as a postdoctoral research associate on a predictive in vitro analytical platform for brain tumour drug efficacy and neurotoxicity safety assessment in the Cancer Biology Unit of the Division of Cancer and Stem Cells.

Expertise Summary

Nanoparticle formulation and optimisation

Atomic-force microscopy, Dynamic light scattering, Chromatography

Solid-dispersions - polymer-drug interactions, stability, dissolution

Emulsions- double emulsions in pancreatic cancer

Polymer synthesis and characterisation

Three-dimensional cell culture- hanging-drops, overlay and co-cultures

Primary tumour tissue and stem cell culture

Flow cytometry, Image analysis, confocal microscopy

Teaching Summary

Project supervision:

Primary supervisor for MPharm student projects 2012-2014

Primary supervisor for MSc Oncology student 2015

Co-supervisor for PhD student 2015 onwards

Research Summary

Neurotoxicity and antitumour efficacy assessment of advanced chemotherapeutic modalities to treat brain tumours using a novel 3D cell culture analytical platform.

The attrition rate for new drugs in Oncology is over 90% partly because preclinical models fail to recapitulate patient response to treatment. The aim of this project is to develop and validate a predictive preclinical platform for benchmarking brain tumour treatment and imaging modalities by:

· Using a previously-developed brain model as an analytical tool to correlate in vitro results with patient response

· Incorporation of patient-derived primary tumour tissue for increased biorelevance

· Utilising advanced imaging methods to explore the interaction of brain tumours and normal brain tissue

· Determination of safety and efficacy of treatments employing advanced materials and nanoparticle delivery systems

Recent Publications

Past Research

Solubility enhancement using solid dispersions, local drug delivery via double emulsions, solid dosage form development

School of Medicine

University of Nottingham
Medical School
Nottingham, NG7 2UH

Contacts: Please see our 'contact us' page for further details